Targeting the complement system: notes on therapeutic strategies for renal cancer.
作者信息
Lasorsa Francesco, Rutigliano Monica, Milella Martina, Ditonno Pasquale, Lucarelli Giuseppe
机构信息
Department of Precision and Regenerative Medicine and Ionian Area-Urology, Andrology and Kidney Transplantation Unit, University of Bari "Aldo Moro", Bari, Italy.
出版信息
Future Med Chem. 2025 May;17(9):979-981. doi: 10.1080/17568919.2025.2498876. Epub 2025 Apr 25.
Abstract
摘要
相似文献
1
Targeting the complement system: notes on therapeutic strategies for renal cancer.靶向补体系统：肾癌治疗策略笔记
Future Med Chem. 2025 May;17(9):979-981. doi: 10.1080/17568919.2025.2498876. Epub 2025 Apr 25.
3
Advances in Complement Inhibitory Strategies for the Treatment of Glomerular Disease: A Rapidly Evolving Field.用于治疗肾小球疾病的补体抑制策略进展：一个快速发展的领域
J Clin Med. 2025 Jun 13;14(12):4204. doi: 10.3390/jcm14124204.
4
Vascular endothelial growth factor-targeted therapy in patients with renal cell carcinoma pretreated with immune checkpoint inhibitors: A systematic literature review.血管内皮生长因子靶向治疗在免疫检查点抑制剂预处理的肾细胞癌患者中的应用：系统文献回顾。
Cancer Treat Rev. 2024 Jan;122:102652. doi: 10.1016/j.ctrv.2023.102652. Epub 2023 Nov 4.
6
Developing Therapies for C3 Glomerulopathy: Report of the Kidney Health Initiative C3 Glomerulopathy Trial Endpoints Work Group.开发C3肾小球病的治疗方法：肾脏健康倡议C3肾小球病试验终点工作组报告
Clin J Am Soc Nephrol. 2024 Sep 1;19(9):1201-1208. doi: 10.2215/CJN.0000000000000505. Epub 2024 Jun 3.
7
Complement C3 inhibition reduces complement activation in clinical platelet concentrates but does not counteract platelet storage lesions.补体C3抑制可降低临床血小板浓缩物中的补体激活，但不能抵消血小板储存损伤。
Platelets. 2025 Dec;36(1):2513298. doi: 10.1080/09537104.2025.2513298. Epub 2025 Jun 25.
8
Therapeutic Strategies for Patients With Metastatic Renal Cell Carcinoma in Whom First-Line Vascular Endothelial Growth Factor Receptor-Directed Therapies Fail.一线血管内皮生长因子受体靶向治疗失败的转移性肾细胞癌患者的治疗策略
J Oncol Pract. 2016 May;12(5):412-20. doi: 10.1200/JOP.2016.011809.
9
A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.系统评价和荟萃分析比较不同全身治疗方案对非透明细胞肾细胞癌的疗效和不良反应。
Eur Urol. 2017 Mar;71(3):426-436. doi: 10.1016/j.eururo.2016.11.020. Epub 2016 Dec 8.
10
The complement system in autoimmune diseases: pathogenesis, diagnostic markers, and therapeutic strategies.自身免疫性疾病中的补体系统：发病机制、诊断标志物及治疗策略。
Inflamm Res. 2025 Jun 30;74(1):93. doi: 10.1007/s00011-025-02061-0.
本文引用的文献
1
Transcriptomic and proteo-metabolic determinants of the grading system in clear cell renal cell carcinoma.透明细胞肾细胞癌分级系统的转录组学和蛋白质代谢决定因素
Urol Oncol. 2025 Mar 12. doi: 10.1016/j.urolonc.2025.02.016.
2
Beyond the Norm: The emerging interplay of complement system and extracellular matrix in the tumor microenvironment.超越常规：肿瘤微环境中补体系统与细胞外基质之间新出现的相互作用
Semin Immunol. 2025 Mar;77:101929. doi: 10.1016/j.smim.2025.101929. Epub 2025 Jan 9.
3
The role of the complement system in the response to cytotoxic therapy.补体系统在细胞毒性治疗反应中的作用。
Semin Immunol. 2025 Mar;77:101927. doi: 10.1016/j.smim.2024.101927. Epub 2025 Jan 6.
4
Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial.难治性非小细胞肺癌中补体因子H靶向抗体GT103：一项1b期剂量递增试验
Nat Commun. 2025 Jan 2;16(1):93. doi: 10.1038/s41467-024-55092-2.
5
The complement system in clinical oncology: Applications, limitations and challenges.临床肿瘤学中的补体系统：应用、局限性与挑战
Semin Immunol. 2025 Mar;77:101921. doi: 10.1016/j.smim.2024.101921. Epub 2024 Dec 18.
6
Changes in complement C3a in the immunotherapy of advanced clear cell renal cell carcinoma.晚期透明细胞肾细胞癌免疫治疗中补体C3a的变化
Transl Androl Urol. 2024 Nov 30;13(11):2518-2526. doi: 10.21037/tau-24-549. Epub 2024 Nov 28.
7
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.贝伐珠单抗联合依维莫司对比舒尼替尼用于晚期肾细胞癌的治疗。
N Engl J Med. 2024 Aug 22;391(8):710-721. doi: 10.1056/NEJMoa2313906.
8
Advanced and Metastatic Non-Melanoma Skin Cancer: Epidemiology, Risk Factors, Clinical Features, and Treatment Options.晚期和转移性非黑色素瘤皮肤癌：流行病学、危险因素、临床特征及治疗选择
Biomedicines. 2024 Jun 28;12(7):1448. doi: 10.3390/biomedicines12071448.
9
The complement system as a target in cancer immunotherapy.补体系统作为癌症免疫治疗的靶点。
Eur J Immunol. 2024 Oct;54(10):e2350820. doi: 10.1002/eji.202350820. Epub 2024 Jul 12.
10
Promotion of an Antitumor Immune Program by a Tumor-specific, Complement-activating Antibody.肿瘤特异性补体激活抗体促进抗肿瘤免疫程序。
J Immunol. 2024 May 15;212(10):1589-1601. doi: 10.4049/jimmunol.2300728.
Zotero 插件